JP2023501584A - Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用 - Google Patents

Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用 Download PDF

Info

Publication number
JP2023501584A
JP2023501584A JP2022527735A JP2022527735A JP2023501584A JP 2023501584 A JP2023501584 A JP 2023501584A JP 2022527735 A JP2022527735 A JP 2022527735A JP 2022527735 A JP2022527735 A JP 2022527735A JP 2023501584 A JP2023501584 A JP 2023501584A
Authority
JP
Japan
Prior art keywords
disease
cancer
pyrazolo
dichlorophenyl
azetidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022527735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501584A5 (https=
Inventor
アーノルド，デイビッド・ジェイ
ロブレス，オマール
ルディシル，デュアン・イー
ウストロー，デイビッド・ジェイ
ジビンスキー，ミハイル
カラボルニ，サミ
Original Assignee
ラプト・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラプト・セラピューティクス・インコーポレイテッド filed Critical ラプト・セラピューティクス・インコーポレイテッド
Publication of JP2023501584A publication Critical patent/JP2023501584A/ja
Publication of JP2023501584A5 publication Critical patent/JP2023501584A5/ja
Priority to JP2025153291A priority Critical patent/JP2026012675A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022527735A 2019-11-13 2020-11-13 Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用 Pending JP2023501584A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025153291A JP2026012675A (ja) 2019-11-13 2025-09-16 Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962935007P 2019-11-13 2019-11-13
US62/935,007 2019-11-13
PCT/US2020/060575 WO2021097339A1 (en) 2019-11-13 2020-11-13 Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025153291A Division JP2026012675A (ja) 2019-11-13 2025-09-16 Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用

Publications (2)

Publication Number Publication Date
JP2023501584A true JP2023501584A (ja) 2023-01-18
JP2023501584A5 JP2023501584A5 (https=) 2023-11-20

Family

ID=73856569

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022527735A Pending JP2023501584A (ja) 2019-11-13 2020-11-13 Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用
JP2025153291A Pending JP2026012675A (ja) 2019-11-13 2025-09-16 Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025153291A Pending JP2026012675A (ja) 2019-11-13 2025-09-16 Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用

Country Status (11)

Country Link
US (2) US12006318B2 (https=)
EP (1) EP4058456A1 (https=)
JP (2) JP2023501584A (https=)
KR (1) KR20220101099A (https=)
CN (1) CN114728972B (https=)
BR (1) BR112022009331A2 (https=)
CA (1) CA3158521A1 (https=)
IL (1) IL292755A (https=)
MX (1) MX2022005795A (https=)
WO (1) WO2021097339A1 (https=)
ZA (1) ZA202204943B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4058456A1 (en) 2019-11-13 2022-09-21 RAPT Therapeutics, Inc. Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
CN121002023A (zh) * 2023-04-24 2025-11-21 浙江华海药业股份有限公司 趋化因子受体调节剂制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525962A (ja) * 2016-07-29 2019-09-12 ラプト・セラピューティクス・インコーポレイテッド ケモカイン受容体調節剤及びそれの使用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
JP2008530211A (ja) * 2005-02-16 2008-08-07 メルク エンド カムパニー インコーポレーテッド ケモカイン受容体のモジュレーターとなる置換ピラゾール
TW201024298A (en) * 2008-09-23 2010-07-01 Palau Pharma Sa (R)-3-(N,N-dimethylamino)pyrrolidine derivatives
US8383812B2 (en) * 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
JP2013031931A (ja) * 2011-08-01 2013-02-14 Hitachi Koki Co Ltd 携帯式作業機
TW201311693A (zh) * 2011-09-02 2013-03-16 Kyowa Hakko Kirin Co Ltd 化學激活激素受體活性調節劑
AR096758A1 (es) * 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
US10246462B2 (en) * 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JP2020533332A (ja) * 2017-09-12 2020-11-19 アルデア バイオサイエンシーズ インク． 障害を処置するためのｃｘｃｒ−２阻害剤
EP3706750A1 (en) 2017-11-06 2020-09-16 RAPT Therapeutics, Inc. Chemokine receptor modulators for treatment of epstein barr virus positive cancer
CN109796457B (zh) * 2019-03-28 2020-03-06 苏州国匡医药科技有限公司 一种2-(3-(氮杂环丁烷-3-基)哌啶-1-基)乙基-1-醇的制备方法及其应用
EP4058456A1 (en) 2019-11-13 2022-09-21 RAPT Therapeutics, Inc. Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019525962A (ja) * 2016-07-29 2019-09-12 ラプト・セラピューティクス・インコーポレイテッド ケモカイン受容体調節剤及びそれの使用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
山野光久: ""医薬品のプロセス研究における結晶多形現象への取り組み"", 有機合成化学協会誌, vol. 65, no. 9, JPN6010003277, 1 September 2007 (2007-09-01), pages 907 - 69, ISSN: 0005591914 *
川口洋子ら, 生活工学研究, vol. 4, no. 2, JPN6015027394, 2002, pages 310 - 317, ISSN: 0005591912 *
平山令明編, 有機化合物結晶作製ハンドブック −原理とノウハウ−, JPN6011053065, 25 July 2008 (2008-07-25), pages 57 - 84, ISSN: 0005591913 *
芦澤 一英、他, 医薬品の多形現象と晶析の科学, JPN7015003233, 20 September 2002 (2002-09-20), pages 305 - 317, ISSN: 0005591911 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005591915 *

Also Published As

Publication number Publication date
CN114728972A (zh) 2022-07-08
JP2026012675A (ja) 2026-01-27
US12006318B2 (en) 2024-06-11
AU2020383625A1 (en) 2022-05-05
ZA202204943B (en) 2023-11-29
KR20220101099A (ko) 2022-07-19
WO2021097339A1 (en) 2021-05-20
TW202132303A (zh) 2021-09-01
EP4058456A1 (en) 2022-09-21
MX2022005795A (es) 2022-06-08
IL292755A (en) 2022-07-01
CA3158521A1 (en) 2021-05-20
US20210139487A1 (en) 2021-05-13
US20240317768A1 (en) 2024-09-26
BR112022009331A2 (pt) 2022-08-09
CN114728972B (zh) 2024-12-10

Similar Documents

Publication Publication Date Title
CN113423685B (zh) 整合应激通路的前药调节剂
JP6504548B2 (ja) Ｂｔｋ阻害剤の塩および固体形態
EP3452448B1 (en) Modulators of the integrated stress pathway
TWI838350B (zh) 抗癌劑
JP2026012675A (ja) Ｃ－ｃケモカイン受容体４型アンタゴニストの結晶形態、およびその使用
US20240132493A1 (en) Imidazopyridine derivatives as sting agonists
JP2024539611A (ja) ３－フルオロ－５－（（（１Ｓ，２ａＲ）－１，３，３，４，４－ペンタフルオロ－２ａ－ヒドロキシ－２，２ａ，３，４－テトラヒドロ－１Ｈ－シクロペンタ［ＣＤ］インデン－７－イル）オキシ）－ベンゾニトリル及びそれの多形を作製するプロセス
JP6422936B2 (ja) ５−ブロモ−インジルビン
JP2024538131A (ja) 膀胱癌処置のための低酸素誘導因子２（アルファ）阻害剤
AU2020383625B2 (en) Crystalline forms of C-C chemokine receptor type 4 antagonist and uses thereof
TWI917338B (zh) Ｃ-ｃ趨化介素受體第四型拮抗劑之晶形及其用途
TW202233613A (zh) 去氧胞苷激酶抑制劑之結晶型及其用途
US20250034115A1 (en) Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
CN115461054A (zh) 延伸因子1-α抑制剂及其用途
US12350241B1 (en) Method for inhibiting proliferation of cancer cells
US12377058B1 (en) Method for inhibiting proliferation of cancer cells
WO2026006739A1 (en) Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors for the treatment of certain diseases
EA053070B1 (ru) Способы получения 3-фтор-5-(((1s,2ar)-1,3,3,4,4-пентафтор-2a-гидрокси-2,2a,3,4-тетрагидро-1h-циклопента[cd]инден-7-ил)окси)бензонитрила и его полиморфов
HK40012051B (en) Modulators of the integrated stress pathway
HK40012051A (en) Modulators of the integrated stress pathway
HK1232155B (zh) Btk抑制剂的盐和固体形式

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250917